ITGB2 and neoplasm: For 54 cases without additional HR characteristics (residual tumor > 1.5cm2, LCAMB, MYC amplification, MYCN amplification in other subgroups than Group 4), full molecular information was available for 22/45 patients ≥ 4 years and all nine patients < 4 years [Fig. 3].